NEW YORK (GenomeWeb News) – Transgenomic today announced a deal with Amgen to develop a CE-IVD test to screen patients with metastatic colorectal cancer for KRAS and NRAS mutations.

The mutations will be identified with Transgenomic's CE-IVD CRC RAScan kits, which use Surveyor-Wave technology. The test will allow physicians to incorporate tumor mutation status into their treatment decisions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.